Pioneering Theranostics: The Future of Personalized Medicine

At the forefront of medical innovation, Alercell is revolutionizing the way we approach cancer treatment. By integrating diagnostics and therapy, our theranostics approach embodies the next frontier in combating cancer, offering hope for early intervention and personalized care.

 Theranostics represents a groundbreaking method in medicine, combining the powers of diagnostics and therapy. It is a two-step process. This approach allows for the early detection of diseases like cancer and leukemia and tailors specific treatments to address them, significantly improving patient outcomes. At Alercell, we leverage this innovative strategy to target various cancers, focusing on the earliest possible intervention through advanced genomic treatments.

Early Diagnostics: We've discovered that in conditions such as Small Cell Lung Cancer, DNA methylation—a process affecting gene expression—can occur up to 43 months before clinical symptoms appear. This critical insight underpins our commitment to early detection, enabling us to intervene before cancer fully manifests.

 Using cutting-edge techniques like RNA interference (RNAi) and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), we can modify the messages sent to DNA, preventing the mutations that lead to cancer. These genomic interventions represent a cornerstone of our strategy to combat cancer at its source. 

 Artificial Intelligence (AI) plays a pivotal role in our approach, analyzing extensive data from Electronic Health Records (EHR) to identify biomarkers of cancer. Our ongoing research into new biomarkers, powered by the speed and capacity of AI, opens up previously unknown avenues for cancer detection and treatment. 

  Our research at Alercell doesn't stop with genomics and AI. By integrating a diverse array of technologies—from biopolymers and nanoparticles to the latest in artificial intelligence—we are crafting the medicine of the 21st century. This multidisciplinary approach allows us to develop highly precise, individualized treatments, ushering in a new era of active and dynamic medicine.